Abstract
A new approach to cancer drug discovery targets molecules important in cancer pathogenesis. This approach is thought to be of greater promise than the antiproliferative screens which discovered cytotoxic agents and dominated cancer drug discovery for 60 years. However, one cannot lose sight of the fact that these targets exist in the cellular environment consisting of many additional influences on target function, and that effective drug treatment will take into account drug uptake, metabolism and elimination at the level of the cell as well as the organism. A key goal is to define for the new millennium a path to cancer drug discovery and development which accounts for the cancer cell phenotype in its totality rather than as arising solely from single molecular targets. The US National Cancer Institute maintains a cell-based drug discovery screen which can define a context for drug action in the milieu of more than 300 molecular targets and thousands of gene expression patterns which have been measured in the 60 human tumour cell lines which comprise the screening panel. The challenge of the millennium will be addressed by molecules active against defined targets but with selectivity of action occurring in the milieu of deregulated cancer cell biology in all its aspects. © 2000 Cancer Research Campaign http://www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Alley MC, Scudiero DA, Monks A, Hursey ML, Czerwinski MJ, Fine DL, Abbott BJ, Mayo JG, Shoemaker RH and Boyd MR (1998 Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 48: 589–601
Drucker BJ and Lydon NB (2000 Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 105: 3–7
Fitzsimmons SA, Workman P, Grever M, Paull KD, Camalier R and Lewis AD (1996 Reductase enzyme expression across the National Cancer Institute tumor cell line panel: correlation with sensitivity to mitomycin C and E09. J Natl Cancer Inst 88: 259–269
Fry DW (1999 Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy: progression from reversible to irreversible inhibitors. Pharmacol Ther 82: 207–218
Garrett MD and Workmann P (1999 Discovering novel chemotherapeutic drugs for the third millennium. Eur J Cancer 35: 2010–2030
Hahnfeldt P, Panigrahy D, Folkman J and Hlatky L (1999 Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy. Cancer Res 59: 4770–4775
Kaelin WG (1999 Choosing anticancer drug targets in the post genomic era. J Clin Invest 104: 1503–1536
Kelland LR, Sharp SY, Rogers PM, Myers TG and Workman P (1999 DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. J Natl Cancer Inst 91: 1940–1949
Koo H, Monks A, Mikheev A, Rubinstein L, Gray-Goodrich M, McWilliams MJ, Alvord WG, O HO, Gazdar AF, Paull KD, Zarbl H and Vande Woude GF (1996 Enhanced sensitivity to 1-β-D-arabinofuranosylcytosine and topoisomerase II inhibitors in tumor cell lines harboring activated ras oncogenes. Cancer Res 56: 5211–5216
Kunkel MW, Kirkpatrick DL, Johnson JI and Powis G (1997 Cell line-directed screening assay for inhibitors of thioredoxin reductase signaling as potential anti-cancer drugs. Anticancer Drug Des 12: 659–670
Metzger R, Leichman CG, Danenberg KD, Danenberg PV, Lenz HJ, Hayashi K, Groshen S, Salonga D, Cohen H, Laine L, Crookes P, Silberman H, Baranda J, Konda B and Leichman L (1998 ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 16: 309–316
Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, Hose C, Langley J, Cronise P, Vaigro-Wolff A, Gray-Goodrich M, Campbell H, Mayo J and Boyd M (1991 Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 83: 757–766
Monks A, Scudiero DA, Johnson GS, Paull KD and Sausville EA (1997 The NCI anti-cancer drug screen: a smart screen to identify effectors of novel targets. Anticancer Drug Des 12: 533–541
Paull KD, Hamel E and Malspeis L (1995 Prediction of biochemical mechanism of action from the in vitro antitumor screen of the National Cancer Institute. Foye WO (ed), In: Cancer Chemotherapeutic Agents, American Chemical Society: Washington, DC pp 9–45
Pommier Y, Kohlhagen G, Bailly C, Waring M, Mazumder A and Kohn KW (1996 DNA-sequence and structure-selective alkylation of guanine N-2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Carribean tunicate Ecteinascidia turbinata. Biochemistry 35: 13303–13309
Ramanujan S, Koenig GC, Padera TP, Stoll BR and Jain RK (2000 Local imbalance of proangiogenic and antiangiogenic factors: a potential mechanism of focal necrosis and dormancy in tumors. Cancer Res 60: 1442–1448
Ross DT, Scherf U, Eisen MB, Perou CM, Rees C, Spellman P, Iyer V, Jeffrey SS, Van de Rijn M, Waltham M, Pergamenschikov A, Lee JC, Lashkari D, Shalon D, Myers TG, Weinstein JN, Botstein D and Brown PO (2000 Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 24: 227–235
Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsai PI, Levy HJ, Leichman CG, Leichman L, Niasio RB and Danenberg PV (2000 Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 6: 1322–1327
Scherf U, Ross DT, Waltham M, Smith LH, Lee JK, Tanabe L, Kohn KW, Reinhold WC, Myers TG, Andrews DT, Scudiero DA, Eisen MB, Sausville EA, Pommier Y, Botstein D, Brown PO and Weinstein JN (2000 A gene expression database for the molecular pharmacology of cancer. Nat Genet 24: 236–244
Simon JA, Szankasi P, Nyugen DK, Ludlow C, Dunstan HM, Roberts CJ, Jensen EL, Hartwell LH and Friend SH (2000 Differential toxicities of anti-cancer agents amoung DNA repair and checkpoint mutants of Saccharomyces cerevisiae. Cancer Res 60: 328–333
Stebbins CE, Russo AA, Schneider C, Rosen N, Hartl FU and Pavletich NP (1997 Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell 89: 239–250
Taamma A, Riofrio M, Cvitkovic E, Meely K, Mekranter B, Jimeno J, Cmaeron L, Beijnen JH and Misset JL (1998 Ecteinascidin-743 (ET-743) 24 hours continuous infusion (CI): Clinical and pharmacokinetic Phase I study in solid tumor patients (Pts). Preliminary results. ASCO Proc,
Weinstein JN, Myers TG, O’Connor PM, Friend SH, Fornace AJ Jr, Kohn KW, Fojo T, Bates SE, Rubinstein LV, Anderson NL, Buolamwini JK, van Osdol WW, Monks AP, Scudiero DA, Sausville EA, Zaharevitz DW, Bunow B, Viswanadhan VN, Johnson GS, Wittes RE and Paull KD (1997 An information-intensive approach to the molecular pharmacology of cancer. Science 275: 343–349
Whitesell L, Mimnaugh EG, De Cosla B, Myers CE and Neckers LM (1994 Inhibition of heat shock protein HSP90-pp60V-src heteroprotein complex formation by benzoquinone ansamycin: roles for stress proteins in oncogenic transfection. Proc Natl Acad Sci USA 91: 8324–8328
Wu L, Smythe AM, Stinson SF, Mullendore LA, Monks A, Scudiero DA, Paull KD, Koutsoukos AD, Rubinstein LV and Boyd MR (1992 Multidrug-resistant phenotype of disease-oriented panels of human tumor cell lines used for anticancer drug screening. Cancer Res 52: 3029–3034
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Sausville, E., Johnson, J. Molecules for the millennium: how will they look? New drug discovery year 2000. Br J Cancer 83, 1401–1404 (2000). https://doi.org/10.1054/bjoc.2000.1473
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1473